MK 8892
Alternative Names: MK-8892Latest Information Update: 19 Dec 2014
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure; Pulmonary arterial hypertension
Most Recent Events
- 19 Dec 2014 Discontinued - Phase-I for Heart failure in Romania, Moldova and Belgium (PO)
- 19 Dec 2014 Discontinued - Phase-I for Pulmonary arterial hypertension (In volunteers) in Belgium (PO)
- 19 Dec 2014 Discontinued - Phase-I for Pulmonary arterial hypertension in Moldova, Germany, Bulgaria, Romania (PO)